March 3, 2026Open Access

Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study

Key Points

Improved progression-free survival correlates with higher BMI, indicating a possible link between weight and treatment effects.
Although drug-drug interactions did not impact overall survival, they did influence certain adverse events related to the drug.
Efficacy and safety of trastuzumab deruxtecan appear robust across various age groups and health conditions in real-world settings.
The findings suggest that personalized monitoring strategies may enhance outcomes for elderly and high-BMI patients with breast cancer.

Abstract

T-DXd efficacy appears consistent across different age groups, although elderly patients showed reduced OS. Higher BMI was associated with improved PFS but increased toxicity. While DDIs did not affect survival outcomes, they influenced specific adverse events. Our results reinforce the efficacy and favorable safety profile of T-DXd in a broad real-world population, including patients with polypharmacy or comorbidities, while highlighting that personalized monitoring and supportive care strategies may be particularly beneficial for elderly patients and those with higher BMI.

Clinical characteristics and drug–drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study

Key Points

Abstract

Cite This Study